Author: seaprwire

SHENZHEN, CHINA – October 30, 2025 – (SeaPRwire) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC). MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China. If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon’s ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon’s product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector. On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China. About AD Indication MG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/

Montréal, Canada – October 16, 2025 – (SeaPRwire) – T-RIZE Group and École de technologie supérieure (ÉTS) are proud to announce that the Industrial Research Chair in Tokenization, established in 2024 under the leadership of Professor Kaiwen Zhang, has secured over CAD $3 million over five years in contributions and funding from major national funds such as Mitacs and the Natural Sciences and Engineering Research Council of Canada (NSERC) through the Mitacs Accelerate – NSERC Alliance Grants program. This highly competitive Canadian funding underscores the strength of a research program already underway since 2024 – one that has consistently delivered transformative results in blockchain sustainability, real-world asset tokenization, and decentralized federated learning. Building Canada’s Resilient Digital Future At the core of this Chair is a patent-pending communication protocol combined with decentralized federated learning frameworks. These innovations are designed to provide infrastructures that are: Resilient: able to withstand disruptions and adapt dynamically to changing conditions Efficient: optimized to reduce costs, latency, and energy consumption at scale Secure: enabling verifiable and trusted exchanges across distributed environments Sovereign: ensuring that Canada retains control over its critical digital systems and data flows Decentralized federated learning enhances tokenization systems by enabling privacy-preserving collaborative intelligence and real-time risk analysis across distributed networks, making infrastructures not only more secure and efficient but also more adaptive to institutional needs. Such capabilities are vital in an increasingly complex world, where robustness, trust, and independence are essential for both national competitiveness and global cooperation. “This recognition from Mitacs, NSERC, and ÉTS affirms our capacity to build sovereign and resilient infrastructures in an era defined by AI. Through Decentralized Machine Learning, T-RIZE ensures that intelligence remains secure, autonomous, and verifiable – the foundation of digital sovereignty in a world where AI power shapes nations.” – Madani Boukalba, CEO, T-RIZE Group Canada’s Vision in Action The over CAD $3 million in funding from Mitacs, a leading innovation organization, and NSERC Alliance is more than financial support – it is recognition that this research is shaping the future of sustainable and sovereign digital infrastructure. By backing proven, high-impact models, Canada is signaling its intent to lead in technologies that matter: efficient networks, scalable intelligent data architectures, and resilient systems aligned with international standards and sustainability goals. Academic and Industrial Leadership Under the guidance of Professor Kaiwen Zhang, one of Canada’s foremost experts in distributed systems, blockchain, and machine learning, the T-RIZE Chair brings together a team of PhD and postdoctoral researchers at ÉTS, working hand in hand with T-RIZE Group. Together, they are turning advanced research into deployable, institutional-grade systems that strengthen Canada’s position as a global leader in innovation. About Mitacs Mitacs places top-tier talent in Canadian firms to support industry-academia collaboration. This helps unlock innovation potential, de-risk R&D for firms, and build lasting academic-industry relationships. Through its national reach and international partnerships, Mitacs enables Canada to develop the next generation of a skilled and innovative workforce. About T-RIZE T-RIZE has the infrastructure to structure and tokenize a wide range of assets – such as real estate, digital bonds, and high-quality carbon credits – into digital structured products enhanced by federated learning for risk analytics. The platform operates across public and privacy-enabled networks, such as the Canton Network. It has the capacity to integrate insurance and digital ratings to make these products collateral-ready, with distribution conducted through regulated broker-dealers. T-RIZE has tokenized over US$100M, with US$1B in signed projects advancing within a US$5B+ pipeline. The RIZE utility token is the access point to its institutional ecosystem. For more information contact:Press Inquiries: press@T-RIZE.ioHead Office: 1155 René-Lévesque West, Suite 2500, Montreal, QC H3B 3X7, CanadaToronto Office: 130 King Street West, Suite 1900, Toronto, ON M5X 1E3, Canada

As the global cryptocurrency industry grows rapidly, enterprises face increasing challenges in market promotion and brand communication. Recently, the leading press release comparison platform PRCompare.com officially launched a global multilingual press release service tailored for cryptocurrency companies, providing an efficient, transparent, and intelligent solution for news distribution. Through PRCompare.com, users can comprehensively compare press release services across different regions and media outlets, clearly understanding fees and service advantages. The platform covers major markets worldwide, including North America, Europe, Asia, and Latin America, helping companies select the most suitable channels to maximize dissemination impact. Moreover, PRCompare.com offers rich multilingual press release packages. Whether in English, Chinese, Japanese, Korean, Spanish, German, or other major languages, companies can quickly generate high-quality press releases that meet local media standards. This multilingual support not only reduces translation costs but also ensures accurate and professional communication of information. The platform provides multiple search modes, allowing users to filter and compare services based on price, coverage region, media type, and expected communication effectiveness. This flexible, efficient search mechanism saves time and enhances the accuracy and overall effect of press release distribution. Industry experts note that as the cryptocurrency market becomes increasingly global, the international influence of a company’s brand depends on the coverage and impact of its press releases. PRCompare.com provides cryptocurrency companies with a measurable, manageable, and effective press release solution through its data-driven comparison tools and multilingual support. Additionally, the platform supports bulk management and scheduled publishing, enabling companies to select optimal posting times across different markets, ensuring synchronized information dissemination worldwide. This feature is especially valuable for cryptocurrency projects aiming to establish brand influence rapidly in multiple countries. In summary, PRCompare.com not only helps companies reduce press release costs and improve efficiency but also enables data-driven decision-making to maximize impact. In the increasingly competitive global cryptocurrency industry, this innovative service offers a powerful new tool. Looking ahead, PRCompare.com plans to continuously enhance platform functionality, add support for more languages and regions, and enrich data analytics capabilities, providing companies with more precise press release strategies and helping cryptocurrency enterprises achieve greater success globally.